



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/192,800	02/07/1994	TETSUJI SUDOH	15870150FWCI	2124

22850 7590 12/15/2003

OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA, VA 22314

EXAMINER

MCGARRY, SEAN

ART UNIT	PAPER NUMBER
----------	--------------

1635

62

DATE MAILED: 12/15/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

08/192,800

Applicant(s)

SUDOH ET AL.

Examiner

Sean R McGarry

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 30 July 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 36-45 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) 36 and 37 is/are allowed.
- 6) ☐ Claim(s) 38-45 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____. 6) ☐ Other: _____

SUPPLEMENTAL DETAILED ACTION

The instant Supplemental Action is mailed to correct the Patent number in the second 102(e) rejection in the Official Action mailed 10/23/03. This Action supercedes the Action mailed 10/23/03.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 38-45 rejected under 35 U.S.C. 102(e) as being anticipated by Seilhamer et al [US 5,674,710].

Seilhamer et al disclose the instantly claimed DNA and peptide sequences in their claims 1-8 and at column 4 and within SEQ ID NOS: 44-46. Applicants claimed sequence fall squarely within the formula of columns 4-5, for example and in claims 1-8. The peptide and nucleic acid of instant claim 39 is specifically disclosed in claim 5 of Seilhamer, for example.

Claims 38-45 rejected under 35 U.S.C. 102(e) as being anticipated by Seilhamer et al [US 5,948,761]. This rejection is maintained for the same reasons set forth in the Official Action mailed 1/30/03.

Seilhamer et al disclose the instantly claimed DNA and peptide sequences in their claims 1-7 and at columns 4-5 and within SEQ ID NOS: 44-46. Applicants claimed sequence fall squarely within the formula of columns 4-5, for example.

Applicant's arguments filed 7/30/03 have been fully considered but they are not persuasive. Applicant essentially argues that there are too many species within the general formula of columns 4-5 of the Seilhamer patent to be anticipatory. This position is not agreed with since the species within the formula are clearly apparent from the disclosure at columns 4-5 especially since the species are subsequences of a peptide that is 32 amino acids in length. Since the peptides are based on subsequences it is the position of the examiner that simply asserting that there may be a large number of

Art Unit: 1635

species within the genus is insufficient to show the invention is not anticipated. For example the peptides of the formula of columns 4-5 and claims 1-2 of Seilhamer are the 32 amino acid peptide or are sequences within that 32 amino peptide and the instantly claimed sequences are clearly immediately envisaged upon a reading of either of the Seilhamer patents specifications and claims. The specific sequence of instant claim 39 is specifically set forth in claim 5 of 5,674,710, for example where the sequence is most clearly envisioned immediately.


Claims 36 and 37 are allowed.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sean R McGarry whose telephone number is (703)305-7028. The examiner can normally be reached on M-Th (6:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on (703) 308-0447. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

SRM


SEAN McGARRY
PRIMARY EXAMINER
1635



ATTORNEYS AT LAW

RECEIVED

DEC 04 2003

TECH CENTER 1600/2900

#61

Docket No.: 147303US0FWC I

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 08/192,800
Applicants: Tetsuji SUDOH, et al.
Filing Date: February 7, 1994
For: PHYSIOLOGICALLY ACTIVE POLYPEPTIDE AND
DNA
Group Art Unit: 1635
Examiner: Sean McGarry

SIR:


Attached hereto for filing are the following papers:

Petition Under 37 C.F.R. 1.181 (A)(3); Copy of Office Action dated 10/23/03

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon
Registration No. 24,618

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Rohitha M. Jayasuriya
Registration No. 50,385